IP Verse

Compositions Of Glp-1 Peptides And Preparation Thereof - EP3488857

The patent EP3488857 was granted to Novo Nordisk on Oct 4, 2023. The application was originally filed on Mar 15, 2013 under application number EP18188815A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3488857

NOVO NORDISK
Application Number
EP18188815A
Filing Date
Mar 15, 2013
Status
Granted And Under Opposition
May 5, 2023
Grant Date
Oct 4, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 7, 2024TER MEER STEINMEISTER & PARTNERADMISSIBLE
HAMM & WITTKOPPMar 7, 2024HAMM & WITTKOPPADMISSIBLE
HEXALMar 7, 2024MAIWALDADMISSIBLE
POLPHARMAMar 7, 2024MAIWALDADMISSIBLE
STRAWMANMar 5, 2024HOFFMANN EITLEADMISSIBLE

Patent Citations (40) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO0046182
DESCRIPTIONWO0192206
DESCRIPTIONWO2005027978
DESCRIPTIONWO2005058954
DESCRIPTIONWO2005058958
DESCRIPTIONWO2006005667
DESCRIPTIONWO2006037810
DESCRIPTIONWO2006037811
DESCRIPTIONWO2006097537
DESCRIPTIONWO2006097538
DESCRIPTIONWO2007121318
DESCRIPTIONWO2008023050
DESCRIPTIONWO2008028859
DESCRIPTIONWO2009030738
DESCRIPTIONWO2009030771
DESCRIPTIONWO2009030774
DESCRIPTIONWO2009083549
DESCRIPTIONWO9319175
DESCRIPTIONWO9629342
DESCRIPTIONWO9630036
DESCRIPTIONWO9808871
DESCRIPTIONWO9943341
DESCRIPTIONWO9943706
DESCRIPTIONWO9943707
DESCRIPTIONWO9943708
OPPOSITIONEP3488857
OPPOSITIONJP4585037B
OPPOSITIONWO2005107462
OPPOSITIONWO2006084164
OPPOSITIONWO2006097537
OPPOSITIONWO2006124047
OPPOSITIONWO2007146234
OPPOSITIONWO2008003050
OPPOSITIONWO2011094531
OPPOSITIONWO2012080471
OPPOSITIONWO2013139694
OPPOSITIONWO2013189988
SEARCHUS2009124639
SEARCHWO2006097537
SEARCHWO2012080471

Non-Patent Literature (NPL) Citations (34) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- HODGSON et al., "The synthesis of peptides and proteins containing non-natural amino acids", Chemical Society Reviews, (20040000), vol. 33, no. 7, pages 422 - 430, XP008067398-
OPPOSITION- Anonymous, "Granulation", Wikipedia, (20240108), pages 1 - 5, Wikipedia , URL: https://en.wikipedia.org/w/index.php?title=Granulation&oldid=1194323726, (20240531), XP093169178-
OPPOSITION- Bhansali A, Maji D, Rao P V, Banerjee S, Kumar H, "Historical Overview of Incretin Based Therapies", Journal of Association of Physicians of India, (20100614), vol. 58, no. Spec. Iss., ISSN 0004-5772, pages 10 - 14, XP093116720-
OPPOSITION- Bhansali A, Maji D, Rao P V, Banerjee S, Kumar H, "Historical Overview of Incretin Based Therapies", JOURNAL OF ASSOCIATION OF PHYSICIANS OF INDIA, ASSOCIATION OF PHYSICIANS OF INDIA, BOMBAY, IN, IN , (20100614), vol. 58, no. Spec. Iss., ISSN 0004-5772, pages 10 - 14, XP093116720-
OPPOSITION- BHANSALI et al., "Historical overview of incretin-based therapies", Journal of Association of Physicians of India, (20100600), vol. 58, pages 10 - 14-
OPPOSITION- Bryan J Ennis, "Theory of Granulation: An Engineering Perspective", Bryan J Ennis, Dilip M Parikh, Handbook of pharmaceutical granulation technology Third edition , Informa healthcare , (20100101), pages 6 - 57, XP093169213-
OPPOSITION- Bryan J Ennis, "Theory of Granulation: An Engineering Perspective", Handbook of pharmaceutical granulation technology Third edition , Informa healthcare , (20100101), pages 6 - 57, XP093169213-
OPPOSITION- C. M. Keck, Et Al, "Kapitel 1.2. Delivery Systeme für die perorale Applikation von Peptiden", Moderne Pharmazeutische Technologie - Lehbuch fur Studierende. 1. Auflage, (20090101), pages 8 - 14, XP055520578-
OPPOSITION- Dilip M Parikh, "Current Granulation Techniques and Research", Handbook of Pharmaceutical Granulation Technology. 3rd ed., Informa Healthcare USA, Inc., (20100101), pages 2 - 3, ISBN 978-1-4398-0789-7, XP055635095-
OPPOSITION- Dilip M Parikh, "Introduction", Dilip M Parikh, Dilip M Parikh, Handbook of Pharmaceutical Granulation Technology, Taylor & Francis , (20050101), pages 1 - 6, ISBN 978-0-8247-2647-8, XP093169174-
OPPOSITION- Dilip M Parikh, "Introduction", Handbook of Pharmaceutical Granulation Technology, Taylor & Francis , (20050101), pages 1 - 6, ISBN 978-0-8247-2647-8, XP093169174-
OPPOSITION- Dilip M. Parikh, "Theory of Granulation : An Engineering Perspective", Handbook of Pharmaceutical Granulation Technology third edition, (20050101), pages 7, 10 - 330, XP055592665-
OPPOSITION- Junginger Hans E, "Delivery Systeme für die perorale Applikation von Peptiden", Modeme Pharmazeutische Technologie - Lehrbuch fur Studierende, (20090101), pages 8 - 14, XP093185827-
OPPOSITION- Rajeev Gokhale, "Wet Granulation in Low- and High-Shear Mixers", Handbook of pharmaceutical granulation technology Third edition, Informa healthcare, pages 183 - 203, Handbook of pharmaceutical granulation technology Third edition, XP093169230-
OPPOSITION- Rajeev Gokhale, "Wet Granulation in Low- and High-Shear Mixers", Rajeev Gokhale, Dilip M Parikh, Handbook of pharmaceutical granulation technology Third edition, Informa healthcare, (20100101), pages 183 - 203, XP093169233-
OPPOSITION- Ronald W Miller, "Roller Compaction Technology", Handbook of pharmaceutical granulation technology Third edition, Informa healthcare, (20100101), pages 163 - 182, XP093169221-
OPPOSITION- Ronald W Miller, "Roller Compaction Technology", Ronald W Miller, Dilip M Parikh, Handbook of pharmaceutical granulation technology Third edition, Informa healthcare, (20100101), pages 163 - 182, XP093169221-
OPPOSITION- Xiaorong He, Pamela J. Secreast, Gregory E. Amidon, "Mechanistic study of the effect of roller compaction and lubricant on tablet mechanical strength", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, (20070501), vol. 96, no. 5, doi:10.1002/jps.20938, ISSN 00223549, pages 1342 - 1355, XP055060697
OPPOSITION- Nauck M. A., J.R. Petrie, G. Sesti, E. Mannucci, J.-P. Courrèges, S. Atkin, M. Düring, C.B. Jensen, S. Heller, "OP 01-2: The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes", Diabetologia, Springer Berlin Heidelberg, Berlin/Heidelberg, Berlin/Heidelberg, (20121001), vol. 55, no. Suppl. 1, doi:10.1007/s00125-012-2688-9, ISSN 0012-186X, pages S7 - S7, XP093171770
OPPOSITION- Michel Marre; Alfred Penfornis, "GLP-1 receptor agonists today", Diabetes research and clinical practice, NL , (20110106), vol. 93, no. 3, doi:10.1016/j.diabres.2011.01.004, ISSN 0168-8227, pages 317 - 327, XP028289489
OPPOSITION- Teng, Y. ; Qiu, Z. ; Wen, H., "Systematical approach of formulation and process development using roller compaction", European journal of pharmaceutics and biopharmaceutics, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL , (20091001), vol. 73, no. 2, doi:10.1016/j.ejpb.2009.04.008, ISSN 0939-6411, pages 219 - 229, XP026652682
OPPOSITION- Teng, Y. ; Qiu, Z. ; Wen, H., "Systematical approach of formulation and process development using roller compaction", European journal of pharmaceutics and biopharmaceutics, NL , (20091001), vol. 73, no. 2, doi:10.1016/j.ejpb.2009.04.008, ISSN 0939-6411, pages 219 - 229, XP026652682
OPPOSITION- C Beglinger, B PoIler, E Arbit, C Ganzoni, S Gass, I Gomez-Orellana, J Drewe, "Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects", Clinical Pharmacology and Therapeutics, Nature Publishing Group, US, US , (20081001), vol. 84, no. 4, doi:10.1038/clpt.2008.35, ISSN 0009-9236, pages 468 - 474, XP008149454
OPPOSITION- C Beglinger , B PoIlerl,, E Arbit, C Ganzonil, S Gass , I Gomez-Orellana , J Drewe, "Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects", Clinical Pharmacology and Therapeutics, US , (20081001), vol. 84, no. 4, doi:10.1038/clpt.2008.35, ISSN 0009-9236, pages 468 - 474, XP008149454
OPPOSITION- R.E. STEINERT, B. POLLER, M.C. CASTELLI, K. FRIEDMAN, A.R. HUBER, J. DREWE AND C. BEGLINGER, "Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects", Clinical Pharmacology and Therapeutics, US , (20091201), vol. 86, no. 6, doi:10.1038/clpt.2009.159, ISSN 0009-9236, pages 644 - 650, XP002635568
OPPOSITION- Michael Goldberg, Isabel Gomez-Orellana, "Challenges for the oral delivery of macromolecules", Nature Reviews Drug Discovery, Nature Pub. Group, (20030401), vol. 2, no. 4, doi:10.1038/nrd1067, ISSN 14741776, pages 289 - 295, XP055085694
OPPOSITION- Bryan . J Ennis, "Theory of Granulation: An Engineering Perspective", Bryan . J Ennis, Dilip M. Parikh, Handbook of Pharmaceutical Granulation Technology Third edition, Informa Healthcare, (20100101), pages 1 - 8, doi:10.3109/9781616310035, XP093169191
OPPOSITION- Guia Bertuzzi, "Effervescent Granulation", Guia Bertuzzi, Dilip M. Parikh, Handbook of Pharmaceutical Granulation Technology Third edition, Informa Healthcare, (20100101), pages 330 - 330, doi:10.3109/9781616310035, XP093169197
OPPOSITION- Steinert Robert E, "Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.", American Journal of Clinical Nutrition, (20101001), vol. 92, no. 4, doi:10.3945/ajcn.2010.29663, ISSN 0002-9165, pages 810 - 817, XP002677085
OPPOSITION- Steinert Robert E, Poller Birk, Castelli M Cristina, Drewe Juergen, Beglinger Christoph, "Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects", American Journal of Clinical Nutrition, Elsevier, (20101001), vol. 92, no. 4, doi:10.3945/ajcn.2010.29663, ISSN 0002-9165, pages 810 - 817, XP002797377
SEARCH- MICHEL MARRE ET AL, "GLP-1 receptor agonists today", DIABETES RESEARCH AND CLINICAL PRACTICE, AMSTERDAM, NL, vol. 93, no. 3, doi:10.1016/J.DIABRES.2011.01.004, ISSN 0168-8227, (20110106), pages 317 - 327, (20110112), XP028289489 [I] 7-8 * page 321, column 1, paragraph l - column 2, paragraph 1; table 3 *
SEARCH- BEGLINGERL C ET AL, "Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects", CLINICAL PHARMACOLOGY AND THERAPEUTICS, NATURE PUBLISHING GROUP, US, vol. 84, no. 4, doi:10.1038/CLPT.2008.35, ISSN 0009-9236, (20081001), pages 468 - 474, (20080326), XP008149454 [X] 1-5,9-11,22 * abstract * * page 473 * [I] 17-21
SEARCH- STEINERT R E ET AL, "Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects", CLINICAL PHARMACOLOGY AND THERAPEUTICS, NATURE PUBLISHING GROUP, US, vol. 86, no. 6, doi:10.1038/CLPT.2009.159, ISSN 0009-9236, (20091201), pages 644 - 650, (20090902), XP002635568 [X] 1-5,9-11,22 * abstract * * page 648 * [I] 17-21
SEARCH- STEINERT ROBERT E ET AL, "Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.", THE AMERICAN JOURNAL OF CLINICAL NUTRITION OCT 2010 LNKD- PUBMED:20720259, (201010), vol. 92, no. 4, ISSN 1938-3207, pages 810 - 817, XP002677085 [X] 1-5,9-11,22 * abstract * * page 811, column 1, paragraph 3 * * page 811, column 2, paragraph 3; figure 6 * * page 816, column 1, paragraph l - column 2, paragraph 1 * [I] 17-21

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents